
Steven Nissen
Contributor at Annals of Internal Medicine
Articles
-
5 days ago |
pharmacytimes.com | Steven Nissen |Alana Hippensteele
CommentaryArticleJune 2, 2025Author(s):,Bempedoic acid is an effective option for statin-intolerant patients or those needing additional low-density lipoprotein cholesterol (LDL-C) reduction, with clinical trials showing cardiovascular benefits, key drug-drug interaction considerations, and special management factors in patients with comorbidities.
-
2 months ago |
hcplive.com | Steven Nissen
Author(s):Fact checked by:Steve Nissen, MD, discusses the phase 2 ALPACA trial and how it informs the potential of lepodisiran for lowering Lp(a). The ALPACA trial demonstrated lepodisiran, a long-acting small interfering RNA therapy, significantly and durably reduces lipoprotein(a) [Lp(a)] levels, with effects lasting up to 18 months.
-
2 months ago |
jamanetwork.com | Steven Nissen |Qiuqing Wang |Stephen Nicholls |Ann Marie Navar
Zerlasiran for the Treatment of Atherosclerotic Cardiovascular Disease—Reply Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a) Steven E. Nissen, MD; Qiuqing Wang, MS; Stephen J. Nicholls, MBBS, PhD; Ann Marie Navar, MD, PhD; Kausik K. Ray, MD, MPhil; Gregory G. Schwartz, MD, PhD; Michael Szarek, PhD; Erik S. G. Stroes, MD, PhD; Roland Troquay, MD; Jannick A. N. Dorresteijn, MD, PhD; Henry Fok, MBBS, PhD; David A.
-
2 months ago |
jamanetwork.com | Yumei Wu |Jiahao Meng |Shuguang Gao |Steven Nissen
Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a) Steven E. Nissen, MD; Qiuqing Wang, MS; Stephen J. Nicholls, MBBS, PhD; Ann Marie Navar, MD, PhD; Kausik K. Ray, MD, MPhil; Gregory G. Schwartz, MD, PhD; Michael Szarek, PhD; Erik S. G. Stroes, MD, PhD; Roland Troquay, MD; Jannick A. N. Dorresteijn, MD, PhD; Henry Fok, MBBS, PhD; David A.
-
Feb 27, 2025 |
bottomlineinc.com | Steven Nissen |Robert Michelin
For people with high cholesterol, lifestyle modifications such as eating better, getting more exercise, losing weight and reducing stress can help curb cardiovascular risk…to some extent. But to substantially lower elevated cholesterol and its attendant risk for heart attack and stroke, long-term use of a prescription cholesterol-lowering medication may be necessary, says Cleveland Clinic cardiovascular disease expert Steven Nissen, MD.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →